RPGLF (Regent Pacific Group) Research & Development: $0.78 Mil (TTM As of Dec. 2025)


RPGLF Regent Pacific Group Ltd RPGLF
7 GF Score
Price $0.01
! 7 Warning Signs
View Full Analysis

What is Regent Pacific Group Research & Development?

Regent Pacific Group RPGLF 7 Research & Development is $0.78 Mil as of Dec. 2025. GuruFocus rates RPGLF with a GF Score™ of 7/100. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Regent Pacific Group's Research & Development for the six months ended in Dec. 2025 was $0.40 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $0.78 Mil.

Regent Pacific Group  (OTCPK:RPGLF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Regent Pacific Group Research & Development Related Terms

Regent Pacific Group Research & Development Historical Data

* Premium members only.

The historical data trend for Regent Pacific Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regent Pacific Group Research & Development Chart

Regent Pacific Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.40 1.22 1.38 0.94 0.78

Regent Pacific Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.53 0.41 0.38 0.40
RPGLF
7GF Score
Regent Pacific Group Ltd RPGLF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regent Pacific Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.78 Mil mean?
Regent Pacific Group (RPGLF) has a Research & Development of $0.78 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Regent Pacific Group and its competitors.
Is Regent Pacific Group's Research & Development too high?
Regent Pacific Group's current Research & Development is $0.78 Mil. Overall, Regent Pacific Group has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Regent Pacific Group's Research & Development compare to ZTS?
Regent Pacific Group's Research & Development of $0.78 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Regent Pacific Group and its competitors. Regent Pacific Group's current Research & Development is $0.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regent Pacific Group stock overvalued right now?
Regent Pacific Group (RPGLF) has a current Research & Development of $0.78 Mil. The current Research & Development is $0.78 Mil. Regent Pacific Group's overall GF Score™ is 7/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Regent Pacific Group (RPGLF), the current Research & Development is $0.78 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regent Pacific Group Business Description

Other Exchanges 00575:Hong KongRPG:Germany
Address 5 Queen\'s Road Central, 8th Floor, Henley Building, Hong Kong, HKG
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Geographically, the Europe; U.S.; and Asia Pacific. It derives maximum revenue from Europe.
7GF Score

Get the complete analysis for RPGLF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price